Tabernero, J;Shitara, K;Zaanan, A;Doi, T;Lorenzen, S;Van Cutsem, E;Fornaro, L;Catenacci, D V T;Fougeray, R;Moreno, S R;Azcue, P;Arkenau, H-T;Alsina, M;Ilson, D H.Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study..ESMO Open.2021.6.4

Hartmann, Oliver;Reissland, Michaela;Maier, Carina R;Fischer, Thomas;Prieto-Garcia, Cristian;Baluapuri, Apoorva;Schwarz, Jessica;Schmitz, Werner;Garrido-Rodriguez, Martin;Pahor, Nikolett;Davies, Clare C;Bassermann, Florian;Orian, Amir;Wolf, Elmar;Schulze, Almut;Calzado, Marco A;Rosenfeldt, Mathias T;Diefenbacher, Markus E.Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease..Front Cell Dev Biol.2021.9

Zimmer, Lisa;Livingstone, Elisabeth;Krackhardt, Angela;Schultz, Erwin S;Göppner, Daniela;Assaf, Chalid;Trebing, Dietrich;Stelter, Kai;Windemuth-Kieselbach, Christine;Ugurel, Selma;Schadendorf, Dirk.Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial..Eur J Cancer.2021.158.72-84

Lewis, Richard;Habringer, Stefan;Kircher, Malte;Hefter, Maike;Peuker, Caroline Anna;Werner, Rudolf;Ademaj-Kospiri, Valëza;Gäble, Alexander;Weber, Wolfgang;Wester, Hans-Jürgen;Buck, Andreas;Herhaus, Peter;Lapa, Constantin;Keller, Ulrich.Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients..EJNMMI Res.2021.11.1

Götze, Thorsten O;Piso, Pompiliu;Lorenzen, Sylvie;Bankstahl, Ulli S;Pauligk, Claudia;Elshafei, Moustafa;Amato, Giuseppe;Reim, Daniel;Bechstein, Wolf O;Königsrainer, Alfred;Mönig, Stefan P;Rau, Beate;Schwarzbach, Matthias;Al-Batran, Salah-Eddin.Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO..BMC Cancer.2021.21.1

Wilhelm, Mathias;Zolg, Daniel P;Graber, Michael;Gessulat, Siegfried;Schmidt, Tobias;Schnatbaum, Karsten;Schwencke-Westphal, Celina;Seifert, Philipp;de Andrade Krätzig, Niklas;Zerweck, Johannes;Knaute, Tobias;Bräunlein, Eva;Samaras, Patroklos;Lautenbacher, Ludwig;Klaeger, Susan;Wenschuh, Holger;Rad, Roland;Delanghe, Bernard;Huhmer, Andreas;Carr, Steven A;Clauser, Karl R;Krackhardt, Angela M;Reimer, Ulf;Kuster, Bernhard.Author Correction: Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics..Nat Commun.2021.12.1

Lorenzen, Sylvie;Reinacher-Schick, Anke;Masetti, Michael.[Modern concepts of systemic treatment for adjuvant and palliative treatment of locally advanced or metastasized esophageal cancer]..Chirurg.2021.92.12.1085-1093

Heilig, C E;Horak, P;Kreutzfeldt, S;Teleanu, V;Mock, A;Renner, M;Bhatti, I A;Hutter, B;Hüllein, J;Fröhlich, M;Uhrig, S;Süße, H;Heiligenthal, L;Ochsenreither, S;Illert, A L;Vogel, A;Desuki, A;Heinemann, V;Heidegger, S;Bitzer, M;Scheytt, M;Brors, B;Hübschmann, D;Baretton, G;Stenzinger, A;Steindorf, K;Benner, A;Jäger, D;Heining, C;Glimm, H;Fröhling, S;Schlenk, R F.Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial..ESMO Open.2021.6.6

Stein, Alexander;Simnica, Donjete;Schultheiß, Christoph;Scholz, Rebekka;Tintelnot, Joseph;Gökkurt, Eray;von Wenserski, Lisa;Willscher, Edith;Paschold, Lisa;Sauer, Markus;Lorenzen, Sylvie;Riera-Knorrenschild, Jorge;Depenbusch, Reinhard;Ettrich, Thomas J;Dörfel, Steffen;Al-Batran, Salah-Eddin;Karthaus, Meinolf;Pelzer, Uwe;Waberer, Lisa;Hinke, Axel;Bauer, Marcus;Massa, Chiara;Seliger, Barbara;Wickenhauser, Claudia;Bokemeyer, Carsten;Hegewisch-Becker, Susanna;Binder, Mascha.PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer..J Immunother Cancer.2021.9.7

Heider, Michael;Nickel, Katharina;Högner, Marion;Bassermann, Florian.Multiple Myeloma: Molecular Pathogenesis and Disease Evolution..Oncology Research and Treatment.2021.44.12.672-681